BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

DARA BioSciences, Inc. Reports Financial Results for the Third Quarter 2012


11/15/2012 9:57:35 AM

RALEIGH, N.C.--(BUSINESS WIRE)--DARA BioSciences, Inc. (NASDAQ: DARA), a specialty pharmaceutical company focused on oncology and oncology supportive care products, and owner of exclusive U.S. marketing rights to Soltamox®, a novel oral liquid formulation of tamoxifen citrate, announced today financial results for the third quarter ended September 30, 2012 in its Quarterly Report on Form 10-Q. For the three months ended September 30, 2012, DARA reported a net loss attributable to common stockholders of $1,983,372, or ($0.16) per share as compared to a net loss of $921,478, or ($0.18) per share for the same period in 2011. The increase in loss was primarily a result of the costs incurred in establishment of a sales and marketing infrastructure to support the promotion of the Company's oncology and oncology supportive care products as well as an increase in general and administrative expenses. As of September 30, 2012, cash and cash equivalents totaled $8,259,476 and marketable securities totaled $788,574.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->